Qsimulate

QSimulate is a technology company that provides quantum-powered simulation solutions designed to accelerate drug discovery and research and development. The company has developed a proprietary quantum mechanics engine—initially known as QUELO and subsequently enhanced by its GPU-optimized GECQO engine—which enables the simulation of complex drug-protein interactions at a subatomic level. By combining high-performance computing resources with unique mixed-precision algorithms, QSimulate's platform is capable of performing predictive molecular simulations with quantum mechanical accuracy up to 1,000 times faster than traditional computational methods, reducing simulation runtimes from months to hours.

These capabilities allow pharmaceutical researchers to more accurately prioritize drug candidates and optimize leads, addressing challenging targets such as covalent binders, metalloproteins, and highly polarizable molecules. By improving the predictive accuracy of binding energy calculations, QSimulate helps its customers reduce experimental costs and accelerate the therapeutic development pipeline. The company operates globally, with headquarters in Boston and additional offices in Berkeley, Ghent, and Tokyo, and serves a diverse customer base that includes major multinational pharmaceutical companies. Founded in 2019 by academic researchers from Northwestern and Caltech, QSimulate continues to advance its technology to support the discovery of new therapies for complex diseases.